A lower dose of efavirenz can be coadministered with rifampicin and isoniazid in tuberculosis patients
A lower dose of efavirenz can be coadministered with rifampicin and isoniazid in tuberculosis patients
Date
2019
Authors
Kaboggoza, Julian P.
Wang, Xinxhu
Neary, Megan
Ayuso, Pedro
Sekaggya-Wiltshire, Christine
Nakalema, Shadia
Owen, Andrew
McClure, Myra
Lamorde, Mohammed
Boffito, Marta
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford Academic Press
Abstract
The ENCORE-1 study demonstrated noninferiority of efavirenz 400 mg once daily (EFV400) when compared with the standard dose (EFV600) [1]. Based on these data, the World Health Organization (WHO) recommends EFV400 as an alternative firstline antiretroviral drug but restricts its use to nonpregnant patients and patients without tuberculosis (TB) [2]. However, a recently published study in United Kingdom human immunodeficiency virus (HIV)-positive patients without TB found EFV concentrations to be adequate when EFV400 was coadministered with rifampicin and isoniazid (RH) [3]. To confirm these results in a TB-infected
population, we conducted an open label, nonrandomized, pharmacokinetic study in HIV/TB coinfected patients in Uganda.
Description
Keywords
Efavirenz lower dose,
Drug co-administration,
Tuberculosis patients,
Rifampicin,
Isoniazid,
Standard dose (EFV600),
First-line antiretroviral drug,
nonpregnant patients,
Tuberculosis patients,
United Kingdom,
Human Immunodeficiency Virus,
EFV concentrations,
TB-infected population,
HIV/TB coinfected patients,
Therapeutic drug monitoring
Citation
Kaboggoza, J. P. et al. (2018). A lower dose of efavirenz can be coadministered with rifampicin and isoniazid in tuberculosis patients. Open Forum Infectious Diseases, 6(2), 1-2.